每經(jing)AI快(kuai)訊，3月14日(ri)，廣(guang)生堂(tang)公(gong)告，公(gong)司創新(xin)(xin)藥(yao)控(kong)股子(zi)公(gong)司廣(guang)生中(zhong)霖于近日(ri)獲得福(fu)建(jian)省(sheng)藥(yao)品監督管(guan)理局核發(fa)的《藥(yao)品生產許可證》（Bh）。目前，公(gong)司正全(quan)力高(gao)效推(tui)進口服小分(fen)子(zi)廣(guang)譜抗(kang)新(xin)(xin)型冠狀病毒3CL蛋白酶抑制劑(ji)一類創新(xin)(xin)藥(yao)物GST-HG171片(pian)的II/III期關鍵性注冊臨床試驗；同(tong)時(shi)，乙肝新(xin)(xin)靶(ba)點新(xin)(xin)藥(yao)GST-HG141、實(shi)體瘤c-Met靶(ba)向新(xin)(xin)藥(yao)GST-HG161等(deng)等(deng)全(quan)球創新(xin)(xin)藥(yao)也(ye)正全(quan)力推(tui)進臨床中(zhong)。